Why is Caplin Point Lab falling/rising?

As of 24-Sep, Caplin Point Laboratories Ltd is experiencing a decline in its stock price, currently at 2,249.60, reflecting a decrease of 6.25 points or 0.28%. The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of 4.05% during this period. Despite being higher than the 20, 50, 100, and 200-day moving averages, it is lower than the 5-day moving average. Additionally, there has been a significant drop in investor participation, with delivery volume decreasing by 51.78% compared to the 5-day average. Over the past week, the stock has underperformed with a return of -3.24%, while the benchmark Sensex has only declined by 1.18%.
In the broader market context, while Caplin Point has shown strong performance over longer periods, including a 17.29% return over the past year and a remarkable 213.14% over three years, its recent performance contrasts sharply with the benchmark's 4.58% year-to-date gain. The stock's valuation is considered expensive, with a high Price to Book Value ratio, which may deter some investors. However, the company has demonstrated high management efficiency and consistent positive results over the last 12 quarters, which could attract institutional investors, as evidenced by a 0.65% increase in their stake. This mix of strong fundamentals and recent price declines suggests that while the company has solid long-term prospects, short-term pressures are currently affecting its stock price.